|Bid||17.37 x 110000|
|Ask||17.40 x 110000|
|Day's range||17.34 - 17.37|
|52-week range||16.21 - 19.90|
|PE ratio (TTM)||34.51|
|Forward Dividend & Yield||N/A (N/A)|
|1y target est||N/A|
GlaxoSmithKline (GSK.L) has won U.S. approval for a new and improved shingles vaccine, the second of three key products for which the British drugmaker expects approval this year. It also secured a recommendation from UK cost authorities for a $700,000 gene therapy for so-called "bubble boy" disease -- a step forward for the field of fixing faulty genes but a tiny sales opportunity. Only three patients have received the gene therapy commercially since its May 2016 approval in Europe.
LONDON, Oct (Shenzhen: 000069.SZ - news) 23 (Reuters) - GlaxoSmithKline (Other OTC: GLAXF - news) has won U.S. approval for a new and improved shingles vaccine, the second of three key products for which the British drugmaker expects approval this year. It also secured a recommendation from UK cost authorities for a $700,000 gene therapy for so-called "bubble boy" disease -- a step forward for the field of fixing faulty genes but a tiny sales opportunity. Only three patients have received the gene therapy commercially since its May 2016 approval in Europe.
Gene therapy is designed to deliver a one-off cure for the patient and drugmakers are typically asking a hefty price that is comparable to the combined costs of alternative life-long treatment. Britain's National Institute for Health and Care Excellence (NICE) said in draft guidance published on Friday that Strimvelis gene therapy used against adenosine deaminase deficiency, or ADA-SCID, improves overall survival compared with standard stem cell transplant therapy.
GlaxoSmithKline's gene therapy for the so-called "bubble boy" disease was approved by Britain's healthcare cost watchdog NICE, despite a price tag of almost 600,000 euros . Gene therapy is designed ...
U.S. regulators have approved a new, more effective vaccine to prevent painful shingles, which is caused by the chickenpox virus.
Shingrix is seen as an improvement over Zostavax, the only currently marketed shingles prevention vaccine, sold by Merck & Co (MRK.N). The vaccine is considered one of the more important products in Glaxo's pipeline, with annual sales forecast to reach $1 billion by 2023, according to Thomson Reuters data. Glaxo said the U.S. Centers for Disease Control and Prevention's advisory committee on immunization practices is expected to vote on a recommendation for the use of Shingrix at its meeting on Wednesday.
Oct (Shenzhen: 000069.SZ - news) 20 (Reuters) - The U.S. Food and Drug Administration approved GlaxoSmithKline (Other OTC: GLAXF - news) 's Shingrix shingles vaccine for use in adults aged 50 and over, a move widely expected after an advisory panel to the agency last month voted unanimously to recommend its approval, the company announced on Friday. Shingrix is seen as an improvement over Zostavax, the only currently marketed shingles prevention vaccine, sold by Merck (Jakarta: 28586808.JK - news) & Co. The vaccine is considered one of the more important products in Glaxo's pipeline, with annual sales forecast to reach $1 billion by 2023, according to Thomson Reuters (Dusseldorf: TOC.DU - news) data.
The performance of GlaxoSmithKline plc's (GSK) new products is likely to be good. Vaccines acquired from Novartis are likely to drive revenues and ease the impact of the loss of key drug, Advair .
As money rushes into China’s fledgling biotechnology sector, Eli Lilly & Co. and other foreign drugmakers are scaling back.
Large-cap pharmas are expected to report encouraging third-quarter results, following J&J's earnings beat. Five out of the six companies are expected to deliver earnings beat this quarter.
GlaxoSmithKline plc (GSK) announced that its vaccine Shingrix has been approved in Canada for the prevention of shingles (herpes zoster) in people aged between 50 years or more.
(Reuters) - Canadian health regulators have approved GlaxoSmithKline's (GSK.L) key shingles vaccine, the company said on Friday. Shingrix, the British pharma company's shingles vaccine for people aged ...
The first placebo-controlled study of two vaccines against the Ebola virus found they both successfully created a powerful antibody response for a year, suggesting they both could be tools to save lives ...
Prime Minister Theresa May will meet GlaxoSmithKline, Vodafone and HSBC and other major companies on Monday to hear what they want from talks on Britain's relationship with the EU after Brexit. Businesses have become increasingly alarmed by the slow progress of negotiations and the prospect that the country could crash out of the trading bloc without a deal in 2019.
G A Chester's quarterly review of 10 FTSE 100 (INDEXFTSE:UKX) industry giants, including GlaxoSmithKline plc (LON:GSK).
As of September 29, 2017, GlaxoSmithKline is trading at a forward PE (price-to-earnings) multiple of 14.2x, which is lower than the industry average of 15.7x.
GlaxoSmithKline’s (GSK) Consumer Healthcare segment has improved its supply chain over the last few years while adding new products to the portfolio.
HIV products reported a 29.0% rise in revenues to 1.1 billion pounds in 2Q17 compared to 2Q16, driven by the strong performances of Tivicay and Triumeq.
GlaxoSmithKline’s (GSK) Pharmaceuticals segment reported a 3.0% rise in revenues at constant exchange rates and a 9.0% positive impact of foreign exchange in 2Q17.
On September 27, 2017, the Japanese Ministry of Health, Labour and Welfare approved Benlysta for the treatment of systemic lupus erythematosus in patients not cured with existing therapies.
U.S. District Judge Nitza Quinones Alejandro in Philadelphia on Friday threw out the case by British investigator Peter Humphrey and his American wife, Yu Yingzeng, who were arrested in 2013 in China after GSK hired them to look into a former employee. The judge said a U.S. Supreme Court ruling barred lawsuits filed under the federal Racketeer Influenced and Corrupt Organizations Act (RICO) over injuries that occur entirely outside the United States such as this one involving incidents in China.